Reuters logo
BRIEF-Pluristem receives positive feedback from FDA and EMA as co prepares for Phase III trial of PLX-PAD
September 26, 2017 / 11:28 AM / 23 days ago

BRIEF-Pluristem receives positive feedback from FDA and EMA as co prepares for Phase III trial of PLX-PAD

Sept 26 (Reuters) - Pluristem Therapeutics Inc:

* Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture

* Pluristem receives positive feedback from FDA and EMA as company prepares for Phase III trial of PLX-PAD to support recovery from hip fracture

* Pluristem- ‍ proposed Phase III trial will be double-blind, randomized, placebo-controlled trial with about 180 patients enrolled in U.S. and Europe​

* Pluristem Therapeutics Inc - Pluristem plans to use results of trial of PLX-PAD to achieve marketing approval in both U.S. And Europe

* Pluristem Therapeutics Inc - ‍plans to submit investigational new drug (IND) and clinical trial application (CTA) for trial in coming months​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below